<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cohen, Y.C.</style></author><author><style face="normal" font="default" size="100%">Joffe, E.</style></author><author><style face="normal" font="default" size="100%">Benyamini, N.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Terpos, E.</style></author><author><style face="normal" font="default" size="100%">Trestman, S.</style></author><author><style face="normal" font="default" size="100%">Held-Kuznetsov, V.</style></author><author><style face="normal" font="default" size="100%">Avivi, I.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Primary failure of bortezomib in newly diagnosed multiple myeloma-understanding the magnitude, predictors, and significance</style></title><secondary-title><style face="normal" font="default" size="100%">Leukemia and Lymphoma</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">bortezomib</style></keyword><keyword><style  face="normal" font="default" size="100%">induction</style></keyword><keyword><style  face="normal" font="default" size="100%">myeloma</style></keyword><keyword><style  face="normal" font="default" size="100%">resistance</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-84953237562&amp;doi=10.3109%2f10428194.2015.1121258&amp;partnerID=40&amp;md5=631ac299af6c7bfa4fa16b1dcfbfdab8</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">57</style></volume><pages><style face="normal" font="default" size="100%">1382 - 1388</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Botezomib-based induction is highly effective for the treatment of newly diagnosed multiple myeloma (NDMM). We investigated the outcomes of NDMM patients who failed to respond to bortezomib-based induction in a real-life clinical setting. In a cohort of 295 consecutive NDMM patients in 3 medical centers, 74 (25%) failed to achieve at least partial response after 4 induction cycles, and were classified as non-responsive. Compared to induction responders, they were older, more frequently anemic, had a higher incidence of del17p and ISS-3, and a worse performance status. In multivariable analysis, bortezomib-based induction failure occurred in 25% of patients and was the strongest independent factor predicting mortality with a 5-fold hazard ratio (95% CI 1.44-8.68). Three-year overall survival in responsive vs. non-responsive patients were 76% vs. 53%, respectively (p &lt; 0.0001). Survival from time of salvage second-line treatment was significantly shorter among induction non-responders vs. responders (25 months vs. not-reached, p = 0.024). © 2015 Taylor &amp; Francis.</style></abstract><issue><style face="normal" font="default" size="100%">6</style></issue><notes><style face="normal" font="default" size="100%">Cited By :2Export Date: 21 February 2017</style></notes></record></records></xml>